{"product_id":"cedars-sinai-advances-in-nuclear-cardiology-cardiac-ct-and-cardiac-mri-38th-annual-case-review-with-the-experts-2026","title":"Cedars Sinai Advances in Nuclear Cardiology, Cardiac CT and Cardiac MRI 38th Annual Case Review with the Experts 2026","description":"\u003ch3 class=\"product_title entry-title\"\u003eCedars Sinai Advances in Nuclear Cardiology, Cardiac CT and Cardiac MRI 38th Annual Case Review with the Experts 2026\u003c\/h3\u003e\r\n\u003cstrong\u003e  4 videos + 53 pdf, size: 6.07 GB\u003c\/strong\u003e\r\n\r\n\u003cb\u003e \u003c\/b\u003e\r\n\r\n\u003cstrong\u003e+ Information:\u003c\/strong\u003e\r\n\r\nFriday, January 23, 2026, 7:30 AM – Sunday, January 25, 2026, 2:55 PM PT, Cedars-Sinai Harvey Morse Conference Center, Los Angeles, CA\r\n\r\n\u003cstrong\u003eTarget Audience\u003c\/strong\u003e\r\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – Cardiology, Imaging, Nuclear Medicine, Radiology\u003c\/div\u003e\r\n\u003cdiv\u003e\n\u003cem\u003eProfessions\u003c\/em\u003e – Nurse, Nurse (Advanced Practice NP CRNA CNM CNS), Physician, Physician Assistant, Radiologic Technologist, Researcher (non-physician), Researcher (physician), Technician\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eOverview\u003c\/strong\u003e\u003c\/div\u003e\r\nA major national healthcare imperative for noninvasive imaging is for the tests to provide value. Nuclear cardiology and cardiac CT studies provide powerful tools for diagnosis, risk assessment, and guiding management of selected patients with known or suspected cardiac disease. In the current environment, imaging must address the combined considerations of improving outcomes and containing costs. To this end, advanced cardiac imaging studies must be ordered on the right patients and optimally performed, interpreted, reported, and acted upon by physicians and allied health professionals. Additionally, effective methods to reduce radiation exposure need to be implemented to maximize patient safety. There is a clear need for physicians ordering, performing and interpreting the tests to understand the issues regarding value-based imaging and to optimally implement this understanding. We meet these educational needs through a live activity entitled: Advances in Nuclear Cardiology, Cardiac CT and Cardiac MRI: 38th Annual Case Review with the Experts. The course is designed to meet the current needs of professionals who perform or request nuclear cardiology or cardiac CT. The course covers the use of these modalities across the spectrum of patients routinely seen by cardiologists in typical day-to-day practice and is designed to improve ordering patterns and increase quality in performing, interpreting, reporting and applying the advanced imaging methods. A unique feature of the program is the extensive use case presentations of each subject as a proven effective teaching tool. It also includes multiple sessions with group faculty discussions. There is a focus on incorporating new guidelines in practice and the latest evidence from clinical trials and registry findings\r\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eObjectives\u003c\/strong\u003e\u003c\/div\u003e\r\n\u003col\u003e\r\n \t\u003cli\u003eIdentify up to date evidence regarding the information provided by tests, the appropriate use of testing an how the tests affect outcomes an costs in coronary and noncoronary heart and aortic disease\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize the implications of 2019 ESC CTA ACCAHA chest pain guidelines on the use of noninvasive testing\u003c\/li\u003e\r\n \t\u003cli\u003eImplement the latest acquisition processing protocols, instrumentation and software for multiple imaging modalities\u003c\/li\u003e\r\n \t\u003cli\u003eExplain how new approaches to functional assessmentsuch as coronary flow reserve, noninvasive fractional flow reserve, and plaque measurementsenhance the information obtained from testing.\u003c\/li\u003e\r\n \t\u003cli\u003eImprove image interpretation and recognition of image artifacts\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize strategies tor educe patient radiation and contrast exposure while conduct high quality studies\u003c\/li\u003e\r\n \t\u003cli\u003eApply optimal protocols for pharmacologic stress testing\u003c\/li\u003e\r\n \t\u003cli\u003eCreate optimal reports that integrate test findings and provide guidance for patient management\u003c\/li\u003e\r\n \t\u003cli\u003eIdentify the latest information regarding how test findings should be used to guide patient management decision\u003c\/li\u003e\r\n \t\u003cli\u003eUse criteria and evidence based strategies to reduce inappropriate testing\u003c\/li\u003e\r\n \t\u003cli\u003eIdentify knowledge gaps regarding blueprints for the CBNC and CBCCT Boards\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cp data-path-to-node=\"4\"\u003e\u003cb data-path-to-node=\"4\" data-index-in-node=\"0\"\u003eTopics\u003c\/b\u003e :\u003c\/p\u003e\r\n\r\n\u003col start=\"1\" data-path-to-node=\"5\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,0,0\"\u003eAI in Cardiac CTA- Quantification of Coronary Plaque- Prediction of Risk-Prediction, and Ischemia\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,1,0\"\u003eAmyloid Quantitation- Decreasing Subjectivity in PYP Interpretation\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,2,0\"\u003eAmyloid Specific PET Tracers\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,3,0\"\u003eBeyond Perfusion with MPI- AI Analysis of CAC, Chamber Volumes, Epicardial Fat, Body Composition and Beyond\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,4,0\"\u003eBeyond the Images- The Essential Role of Excercise and Functional Assessment in Cardiac Testing\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,5,0\"\u003eCardiac MRI and PET in Microvascular Disease\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,6,0\"\u003eCardiac MRI in Sarcoidosis and Other Inflammatory Cardiomyopathies\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,7,0\"\u003eCase Review- CTA in Valvular Disease\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,8,0\"\u003eCase-Based Interpretation of Flurpiridaz MPI\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,9,0\"\u003eCentral Role of Cardiac CT in Structural Heart Disease\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,10,0\"\u003eChanging the Outlook in Cardiac Amyloidosis- Current and Novel Therapies\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,11,0\"\u003eChoosing Between Flurpiridaz and Rubidium\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,12,0\"\u003eClass IA Guideline Recommendation for Chest Pain- What Evidence Brought Coronary CTA Here\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,13,0\"\u003eClinical Value of Myocardial Blood Flow Measurement\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,14,0\"\u003eCombining Anatomy and Physiology with SPECT and PET. Crucial Role of CAC Scanning in Patients\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,15,0\"\u003eCoronary Artery Calcium (CAC) Scanning- Central Role in Preventive Cardiology\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,16,0\"\u003eCoronary CT in Mitral Valve and Afib- Watchman and TMVR\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,17,0\"\u003eCoronary CTA and FFRct for the Interventionalist- Use in Planning and Guiding PCI\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,18,0\"\u003eCoronary CTA in Asymptomatic Patients\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,19,0\"\u003eCoronary CTA in Evaluation of Patients with Known CAD (Stents, CABG)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,20,0\"\u003eCoronary CTA in Evaluation of Suspected CAD in Daily Practice\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,21,0\"\u003eCoronary CTA- Special Consideration for Women\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,22,0\"\u003eDebate- Coronary CTA Will Replace Stress Testing\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,23,0\"\u003eEvolving Trends in CAD- Shifting Risk Factors, Symptoms, and Mortality Drivers\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,24,0\"\u003eFDG PET in Sarcoidosis- Practical Considerations\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,25,0\"\u003eFlurpiridaz- The Ideal PET Perfusion Tracer\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,26,0\"\u003eGame-Show Jeopardy- Cardiac CT, Nuclear, and CMR\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,27,0\"\u003eHow to Integrate Stress Myocardial Blood Flow and Flow Reserve in Clinical Reporting and Guiding Therapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,28,0\"\u003eHow to Start Using Flurpiridaz- Lab Preparation, Protocols, Exercise vs Pharmacologic Stress\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,29,0\"\u003eIncorporating Artificial Intelligence in Interpreting Reports of SPECT MPI- Case Interpretations\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,30,0\"\u003eIntegrating Visual and Quantitative Analyses of SPECT and PET- Improving Your Scan Interpretation- Case Illustrations\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,31,0\"\u003eIscheia Evaluation with Coronary CTA- FFRct\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,32,0\"\u003eMBF-MFR with Cardiac MRI- Becoming Routine in Stress MRI\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,33,0\"\u003eMBF-MFR with PET- How to Perform Quality Control, Interpret and Report\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,34,0\"\u003eMFR with SPECT- Ready for Prime Time-\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,35,0\"\u003eMRI in Cardiac Amyloidosis- Strengths and Limitations\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,36,0\"\u003eMy Best Teaching Cases\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,37,0\"\u003eMyocardial Bridging and Coronary Anomalies on Coronary CTA- When is Further Assessement Needed and What Should It Be\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,38,0\"\u003eMyocardial Viability- CMR and FDG PET\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,39,0\"\u003eNuclear Cardiology in 2026 and Beyond\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,40,0\"\u003ePerfusion and Blood Flow Quantitation- Transmural and Subendocardial\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,41,0\"\u003ePET or SPECT- Right Test for the Right Patient\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,42,0\"\u003ePharmacologic Stress- Combined with Exercise or Alone- What You Need to Know\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,43,0\"\u003ePlaque Imaging in Guiding Patient Management\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,44,0\"\u003eProblems fo Coronary CTA- Small Stents, CAC, Breathing\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,45,0\"\u003ePutting it All Together- Value-Based Use of Cardiac Imaging\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,46,0\"\u003eQuantitation in Sarcoidosis Interpretation\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,47,0\"\u003eQuantitative Plaque Analysis in Tracking Progression of Disease\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,48,0\"\u003eStress First SPECT Protocols- Improved Defect Detection, Stress Only Procedures\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,49,0\"\u003eTc-99m Pyrophosphate (PYP) Imaging- Acquisition, Processing, Interpretation PET-based Radiotracers\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,50,0\"\u003eThe Disease, the Suspicion-Diagnostic Pathways, and Treatments\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,51,0\"\u003eThe Future of Cardiac CT- Photon Counting CT and More\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ol\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954678108258,"sku":"MED-AMB08019","price":60.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Cedars-Sinai-Advances-in-Nuclear-Cardiology-Cardiac-CT-and-Cardiac-MRI-38th-Annual-Case-Review-with-the-Experts-2026.jpg?v=1779382258","url":"https:\/\/meducourse.com\/products\/cedars-sinai-advances-in-nuclear-cardiology-cardiac-ct-and-cardiac-mri-38th-annual-case-review-with-the-experts-2026","provider":"Meducourse","version":"1.0","type":"link"}